著者

Komeda Hidetsugu Kosaka Hirotaka Saito Daisuke N Inohara Keisuke Munesue Toshio Ishitobi Makoto Sato Makoto Okazawa Hidehiko

出版者

BioMed Central Ltd.

雑誌

Molecular Autism (ISSN:20402392)

巻号頁・発行日

vol.4, 2013-06-24

被引用文献数

10

---

自閉症スペクトラム障害をもつ方々は、自分に似た物語を検索しやすい. 京都大学プレスリリース. 2013-06-24.

著者

Sato Wataru Toichi Motomi Uono Shota Kochiyama Takanori

出版者

BioMed Central Ltd.

雑誌

BMC Neuroscience (ISSN:14712202)

巻号頁・発行日

vol.13, 2012-08-13

被引用文献数

105

---

自閉症スペクトラム障害でミラーニューロン回路の不全. 京都大学プレスリリース. 2012-08-15.

著者

Komatsu Yoshito Ishioka Chikashi Shimada Ken Yamada Yasuhide Gamoh Makio Sato Atsushi Yamaguchi Tatsuro Yuki Satoshi Morita Satoshi Takahashi Shin Goto Rei Kurihara Minoru

出版者

BioMed Central Ltd.

雑誌

BMC Cancer (ISSN:14712407)

巻号頁・発行日

vol.15, 2015-09-09

被引用文献数

13

---

Background: Metastatic colorectal cancer carries a poor prognosis and cannot be cured by currently available therapy. Chemotherapy designed to prolong survival and improve the quality of life (QOL) of patients is the mainstay of treatment. Standard regimens of FOLFOX/bevacizumab and CapeOX/bevacizumab can cause neurotoxicity, potentially disrupting treatment. The results of 3 phase II studies of combination therapy with S-1, irinotecan, and bevacizumab showed comparable efficacy to mFOLFOX6/bevacizumab and CapeOX/bevacizumab, without severe neurotoxicity. Therefore, the establishment and evaluation of S-1-containing irinotecan-based regimens for first-line treatment are expected to become more important. Methods: The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy. Patients will be randomly assigned to either the control group (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) or study group (SIRB or IRIS/bevacizumab). The target sample size is 450 patients. The primary endpoint is progression-free survival (PFS), and the secondary endpoints are overall survival (OS), response rate (RR), time to treatment failure (TTF), relative dose intensity (RDI), the incidence and severity of adverse events, quality of life (QOL), quality-adjusted life years (QALY), health care costs, and relations between biomarkers and treatment response (translational research, TR). Discussion: The results of this study will provide important information that will help to improve the therapeutic strategy for metastatic colorectal cancer, and we believe that this study is very meaningful from the perspective of comparative effectiveness research. Trial registration:UMIN000007834

著者

Nakagawa Takayuki Kumakawa Kozo Usami Shin-ichi Hato Naohito Tabuchi Keiji Takahashi Mariko Fujiwara Keizo Sasaki Akira Komune Shizuo Sakamoto Tatsunori Hiraumi Harukazu Yamamoto Norio Tanaka Shiro Tada Harue Yamamoto Michio Yonezawa Atsushi Ito-Ihara Toshiko Ikeda Takafumi Shimizu Akira Tabata Yasuhiko Ito Juichi

出版者

BioMed Central Ltd.

雑誌

BMC medicine (ISSN:17417015)

巻号頁・発行日

vol.12, 2014-11-19

被引用文献数

74

---

突発性難聴に対する新規治療法の有効性を報告. 京都大学プレスリリース. 2014-12-10.

著者

Takeda Satoko Park Jong-Hoon Kawashima Eriko Ezawa Ikuko Omi Naomi

出版者

BioMed Central Ltd.

雑誌

Journal of the International Society of Sports Nutrition

巻号頁・発行日

vol.10, pp.35, 2013-08

被引用文献数

13 1

---

BackgroundSome studies have shown that dietary hydrolyzed collagen peptides (HC) effectively prevent age-related bone loss. However, it is not known whether the intake of HC also has positive effect on bone mass or strength when combined with exercise during growth phase.MethodsWe examined the effects of 11 weeks of HC intake and running exercise on bone mass and strength in growing rats. Rats were randomized into four groups, the 20% casein group (Casein20), the 40% casein group (Casein40), the 20% HC group (HC20), and the 40% HC group (HC40). Each group was further divided into exercise groups (Casein20 + Ex, Casein40 + Ex, HC20 + Ex, HC40 + Ex) and non-exercise group (Casein20, Casein40, HC20, HC40). In the HC intake groups, 30% of casein protein was replaced with HC. Exercise group rats were trained 6 days per week on a treadmill (25–30 m/min, 60 min) for 60 days. After being sacrificed, their bone mineral content (BMC) and bone strength were evaluated.ResultsExercise and dietary HC effects were observed in the adjusted BMC of lumbar spine and tibia among the 20% protein groups (p < 0.001 for exercise; p < 0.05 for dietary HC, respectively). These effects were also noted in the adjusted wet weight and dry weight of femur among the 20% protein groups (p < 0.001, p < 0.01 for exercise; p < 0.01, p < 0.001 for dietary HC, respectively). On the other hand, in adjusted bone breaking force and energy, dietary HC effect was not significant. Among the 40% protein groups, similar results were obtained in the adjusted BMC, femoral weight, bone breaking force, and energy. There were no differences between the 20% protein groups and the 40% protein groups.ConclusionsThe present study demonstrated that moderate HC intake (where the diet contains 20% protein, of which 30% is HC) increased bone mass during growth period and further promoted the effect of running exercise. On the other hand, a higher HC intake (where the diet contains 40% protein, of which 30% is HC) had no more beneficial effect on bone mass than the moderate HC intake.

著者

Oshiro Yoshiko Mizumoto Masashi Okumura Toshiyuki Sugahara Shinji Fukushima Takashi Ishikawa Hitoshi Nakao Tomohei Hashimoto Takayuki Tsuboi Koji Ohkawa Haruo Kaneko Michio Sakurai Hideyuki

出版者

BioMed Central Ltd.

雑誌

Radiation oncology (ISSN:1748717X)

巻号頁・発行日

vol.8, pp.142, 2013-06

被引用文献数

33 2

---

PurposeTo evaluate the efficacy of proton beam therapy (PBT) for pediatric patients with advanced neuroblastoma.MethodsPBT was conducted at 21 sites in 14 patients with neuroblastoma from 1984 to 2010. Most patients were difficult to treat with photon radiotherapy. Two and 6 patients were classified into stages 3 and 4, respectively, and 6 patients had recurrent disease. Seven of the 8 patients who received PBT as the initial treatment were classified as the high risk group. Twelve patients had gross residual disease before PBT and 2 had undergone intraoperative radiotherapy before PBT. Five patients received PBT for multiple sites, including remote metastases. Photon radiotherapy was used in combination with PBT for 3 patients. The PBT doses ranged from 19.8 to 45.5 GyE (median: 30.6 GyE).ResultsSeven patients are alive with no evidence of disease, 1 is alive with disease progression, and 6 died due to the tumor. Recurrence in the treatment field was not observed and the 3-year locoregional control rate was 82%. Severe acute radiotoxicity was not observed, but 1 patient had narrowing of the aorta and asymptomatic vertebral compression fracture at 28 years after PBT, and hair loss was prolonged in one patient.ConclusionPBT may be a better alternative to photon radiotherapy for children with advanced neuroblastoma, and may be conducted safely for patients with neuroblastoma that is difficult to manage using photon beams.

著者

Zhang Wei Tsurushima Hideo Oyane Ayako Yazaki Yushin Sogo Yu Ito Atsuo Matsumura Akira

出版者

BioMed Central Ltd.

雑誌

Journal of biomedical science (ISSN:10217770)

巻号頁・発行日

vol.18, pp.62, 2011-08

被引用文献数

28 16

---

BackgroundSafe and efficient gene transfer systems are needed for tissue engineering. We have developed an apatite composite layer including the bone morphogenetic protein-2 (BMP-2) gene and fibronectin (FB), and we evaluated its ability to induce bone formation.MethodsAn apatite composite layer was evaluated to determine the efficiency of gene transfer to cells cultured on it. Cells were cultured on a composite layer including the BMP-2 gene and FB, and BMP-2 gene expression, BMP-2 protein concentrations, alkaline phosphatase (ALP) activity, and osteocalcin (OC) concentrations were measured. A bone defect on the cranium of rats was treated with hydroxyapatite (HAP)-coated ceramic buttons with the apatite composite layer including the BMP-2 gene and FB (HAP-BMP-FB). The tissue concentration of BMP-2, bone formation, and the expression levels of the BMP-2, ALP, and OC genes were all quantified.ResultsThe apatite composite layer provided more efficient gene transfer for the cultured cells than an apatite composite layer without FB. The BMP-2 concentration was approximately 100~600 pg/mL in the cell-culture medium. Culturing the cells on the apatite composite layer for 27 days increased ALP activity and OC concentrations. In animal experiments, the tissue concentrations of BMP-2 were over 100 pg/mg in the HAP-BMP-FB group and approximately 50 pg/mg in the control groups. Eight weeks later, bone formation was more enhanced in the HAP-BMP-FB group than in the control groups. In the tissues surrounding the HAP button, the gene expression levels of ALP and OC increased.ConclusionThe BMP-2 gene-FB-apatite composite layer might be useful for bone engineering.

著者

Tomonaga Masaki Imura Tomoko

出版者

BioMed Central Ltd.

雑誌

Behavioral and brain functions : BBF (ISSN:17449081)

巻号頁・発行日

vol.6, 2010-07

被引用文献数

9

---

BACKGROUND: Humans readily perceive whole shapes as intact when some portions of these shapes are occluded by another object. This type of amodal completion has also been widely reported among nonhuman animals and is related to pictorial depth perception. However, the effect of a cast shadow, a critical pictorial-depth cue for amodal completion has been investigated only rarely from the comparative-cognitive perspective. In the present study, we examined this effect in chimpanzees and humans. RESULTS: Chimpanzees were slower in responding to a Pacman target with an occluding square than to the control condition, suggesting that participants perceptually completed the whole circle. When a cast shadow was added to the square, amodal completion occurred in both species. On the other hand, however, critical differences between the species emerged when the cast shadow was added to the Pacman figure, implying that Pacman was in the sky casting a shadow on the square. The cast shadow prevented, to a significant extent, compulsory amodal completion in humans, but had no effect on chimpanzees. CONCLUSION: These results suggest that cast shadows played a critical role in enabling humans to infer the spatial relationship between Pacman and the square. For chimpanzees, however, a cast shadow may be perceived as another "object". A limited role for cast shadows in the perception of pictorial depth has also been reported with respect to human cognitive development. Further studies on nonhuman primates using a comparative-developmental perspective will clarify the evolutionary origin of the role of cast shadows in visual perception.